| Literature DB >> 25685804 |
Jing Wang1, Xiaoshan Tang1, Yun Shen1, Guangwei Shang1, Li Fang1, Raorao Wang1, Yuanzhi Xu1.
Abstract
This study aimed to assess generic health-related quality of life (HRQoL), pain intensity, and anxiety levels and the relationship between the three aspects in healthy young Chinese orthodontic patients in the early stage of orthodontic treatment. We enrolled 252 eligible participants (10-29 years old) to complete validated Chinese versions of questionnaires, including the State-Trait Anxiety Inventory (S-AI), the visual analogue scale (VAS), and the Short-Form 36-Item Health Survey (SF-36) at baseline and on days 1, 2, 3, 7, 14, and 30 after initial archwire placement (SF-36 only at baseline and day 30). The response rate was 96% (243 of 252). SF-36 had moderate reliability (Cronbach's alpha coefficient exceeding 0.7, good fit on day 30). Statistical significant changes were observed in physical function (P < 0.01), body pain (P = 0.01), and general health (P < 0.01) domains. Spearman correlation coefficients for SF-36 with S-AI were -0.131~-0.515 (P < 0.05); SF-36 with VAS were -0.141~-0.273 (P < 0.05), indicating significant but moderate negative correlations between HRQoL and pain/anxiety. Overall, the application of SF-36 in assessing HRQoL is reluctantly suitable for young Chinese orthodontic patients in the early stage of orthodontic treatment. Early treatment-related pain and anxiety are important factors in HRQoL.Entities:
Mesh:
Year: 2015 PMID: 25685804 PMCID: PMC4317575 DOI: 10.1155/2015/725913
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Means and standard deviations of the scores of the SF-36 domains after the initial archwire placement in the study participants.
| Physical functioning | Physical role | Body pain | General health | Vitality | Social functioning | Emotional role | Mental health | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mean | SD | mean | SD | mean | SD | mean | SD | mean | SD | mean | SD | mean | SD | mean | SD | |
| All | 95.62 | 10.45 | 88.31 | 25.44 | 77.09 | 14.49 | 80.25 | 16.82 | 74.83 | 15.24 | 90.60 | 12.89 | 75.98 | 69.63 | 79.21 | 15.37 |
| 10–16 years | 94.90 | 11.76 | 90.78 | 22.46 | 78.20 | 14.32 | 84.08 | 16.06 | 77.60 | 15.44 | 92.40 | 10.91 | 84.10 | 82.53 | 82.17 | 14.51 |
| 17–29 years | 96.74 | 7.91 | 84.47 | 29.21 | 75.37 | 14.67 | 74.28 | 16.32 | 70.51 | 13.93 | 87.80 | 15.12 | 63.33 | 39.56 | 74.60 | 15.60 |
| Male | 94.95 | 11.97 | 87.10 | 26.49 | 74.95 | 14.61 | 80.81 | 15.30 | 73.53 | 14.75 | 89.71 | 13.08 | 72.49 | 34.71 | 78.11 | 15.93 |
| 10–16 years | 94.08 | 12.54 | 87.25 | 25.45 | 74.22 | 14.43 | 83.28 | 14.52 | 75.67 | 14.66 | 90.90 | 12.02 | 74.82 | 32.95 | 80.53 | 15.23 |
| 17–29 years | 96.25 | 11.08 | 86.88 | 28.30 | 76.05 | 14.99 | 77.10 | 15.88 | 70.33 | 14.50 | 87.93 | 14.50 | 69.00 | 37.35 | 74.48 | 16.45 |
| Female | 96.08 | 9.25 | 89.16 | 24.75 | 78.59 | 14.27 | 79.86 | 17.85 | 75.73 | 15.55 | 91.22 | 12.76 | 78.42 | 86.07 | 79.98 | 14.97 |
| 10–16 years | 95.45 | 11.24 | 93.18 | 19.96 | 80.92 | 13.67 | 84.63 | 17.09 | 78.92 | 15.89 | 93.42 | 10.03 | 90.43 | 103.30 | 83.28 | 13.98 |
| 17–29 years | 97.09 | 4.48 | 82.73 | 30.00 | 74.87 | 14.55 | 72.24 | 16.47 | 70.64 | 13.64 | 87.71 | 15.68 | 59.20 | 40.93 | 74.69 | 15.11 |
Comparison of scores of SF-36 domains at baseline and day 30 after initial treatment*.
| SF-36 (baseline), SF-36 (30th day) | SF-36 (baseline), SF-36 (30th day) |
|
| |||
|---|---|---|---|---|---|---|
| Median | Interquartile range | Mean | SD | |||
| PF | 0 | 5 | −1.276 | 9.339 | −3.48 | <0.01** |
| RP | 0 | 0 | −0.045 | 30.742 | −0.26 | 0.8 |
| BP | 0 | 16 | 2.695 | 15.927 | −2.71 | 0.01** |
| GH | −2 | 15 | −4.276 | 15.583 | −4.67 | <0.01** |
| VT | 0 | 20 | −0.403 | 15.154 | −0.26 | 0.8 |
| SF | 0 | 24 | 0.333 | 15.160 | −0.24 | 0.81 |
| RE | 0 | 33 | −3.021 | 91.667 | −1.29 | 0.2 |
| MH | 0 | 20 | −0.955 | 16.418 | −1.48 | 0.14 |
*Analysis of the 8 domains scores of SF-36 before and after the initial treatment by Wilcoxon signed-rank test.
**The differences of domain scores before and after the initial treatment were statistically significant (P < 0.05).
(1) Physical functioning: PF; (2) role limitations due to physical problems: RP; (3) body pain: BP; (4) social functioning: SF; (5) general mental health: MH; (6) role limitations because of emotional problems: RE; (7) vitality: VT; and (8) general health perceptions: GH.
Figure 1Median of VAS scores in the study subject.
Figure 2Median of state anxiety scores in the study subject.
Means (SD) and correlation analysis results of VAS scores and state anxiety scores in the study subject*.
| 1st day | 2nd day | 3rd day | 7th day | 14th day | 30th day | |
|---|---|---|---|---|---|---|
| VAS | 59 (28) | 53 (31) | 36 (35) | 6 (16) | 1 (5) | 0 (2) |
| State anxiety | 38 (15) | 38 (17) | 36 (15) | 31 (13) | 30 (15) | 31 (14) |
|
| 0.171 | 0.246 | 0.189 | 0.310 | 0.333 | 0.125 |
|
| 0.008** | <0.001** | 0.003** | <0.001** | <0.001** | 0.055 |
*Analysis of the relevance between VAS scores and state anxiety scores on each observation point by Spearman rank correlation.
**The rank correlation coefficients were statistically significant (P < 0.05).
Correlation analysis of SF-36 domain scores between VAS and S-AI scores in the study subjects*.
| PF-VAS | BP-VAS | GH-VAS | PF-SAI | BP-SAI | GH-SAI | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| 1st day | −0.141 | 0.029** | −0.033 | 0.613 | −0.109 | 0.092 | −0.109 | 0.090 | −0.243 | <0.001** | −0.354 | <0.001** |
| 2nd day | −0.124 | 0.055 | −0.133 | 0.040** | −0.161 | 0.013** | −0.204 | 0.001** | −0.230 | <0.001** | −0.369 | <0.001** |
| 3rd day | −0.115 | 0.076 | −0.153 | 0.018** | −0.170 | 0.008** | −0.207 | 0.001** | −0.143 | 0.026** | −0.360 | <0.001** |
| 7th day | −0.048 | 0.462 | −0.139 | 0.032** | −0.212 | 0.001** | −0.166 | 0.010** | −0.268 | <0.001** | −0.413 | <0.001** |
| 14th day | −0.045 | 0.487 | −0.151 | 0.020** | −0.273 | <0.001** | −0.236 | <0.001** | −0.194 | 0.002** | −0.515 | <0.001** |
| 30th day | −0.012 | 0.857 | −0.143 | 0.028** | −0.222 | 0.001** | −0.205 | 0.001** | −0.131 | 0.042** | −0.466 | <0.001** |
*Analysis of the relevance between SF-36 domain scores (on day 30) and VAS/state anxiety scores on each observation point by Spearman rank correlation.
**The rank correlation coefficients were statistically significant (P < 0.05).